SCHEMBL14478703

SCHEMBL14478703

COc1ncc(-c2ccccc2)c(F)c1C

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SQOR Q9Y6N5 4/20 0.49
▸ MAPT P10636 2/20 0.45
▸ CASP1 P29466 1/20 0.45
▸ ALOX5AP P20292 2/20 0.43
▸ FEN1 P39748 2/20 0.43
▸ KMT2A Q03164 2/20 0.41
▸ EDNRA P25101 1/20 0.38
▸ PDCD1 Q15116 1/20 0.37
▸ CD274 Q9NZQ7 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ SMN1; SMN2 Q16637 3/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37
▸ HPGD P15428 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ MEN1 O00255 1/20 0.37
▸ NPSR1 Q6W5P4 1/20 0.37
▸ GLA P06280 1/20 0.36
▸ GAA P10253 1/20 0.36
▸ HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6916456 0.85 ALOX5AP (0.51) SQORMAPTCASP1ALOX5APFEN1
SCHEMBL24713444 0.84 SQOR (0.53) SQORMAPTCASP1ALOX5APFEN1
SCHEMBL2434147 0.75 MAPT (0.48) SQORMAPTCASP1ALOX5APFEN1
SCHEMBL28097912 0.75 MAPT (0.41) SQORMAPTCASP1ALOX5APFEN1
SCHEMBL13144468 0.74 SQOR (0.57) SQORMAPTCASP1KMT2APDCD1
SCHEMBL20764961 0.72 MAPT (0.56) SQORMAPTCASP1ALOX5APFEN1
SCHEMBL30439186 0.72 MAPT (0.56) SQORMAPTCASP1ALOX5APFEN1
SCHEMBL17703511 0.72 SQOR (0.51) SQORMAPTCASP1KMT2AALDH1A1
SCHEMBL11741475 0.70 NCOA1 (0.52) SQORMAPTCASP1KMT2AEDNRA
SCHEMBL9756304 0.70 MAPT (0.45) SQORMAPTCASP1KMT2AEDNRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9309199-B2 Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders MERCK SHARP & DOHME CORP. (US) 2016-04-12 — — US disclosed
US-20130005744-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS MERCK SHARP & DOHME LLC 2013-01-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005744-A1 INHIBITORS OF CATECHOL O-METHYL TRANSFERASE AND THEIR USE IN THE TREATMENT OF PSYCHOTIC DISORDERS COMT, PNMT, TPMT SQOR 176/4885MAPT 220/4885CASP1 4086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback